Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT06145360

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
SINA Health Education and Welfare Trust (from the registry)
Registry
  • NCT NCT06145360
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06145360. Randomized; double masking; primary purpose treatment. Start 2023-12-01 (actual); primary completion 2024-03-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
Condition
Glucose Metabolism Disorders
Condition
Diabetes Mellitus, Type 2
Condition
Hypoglycemic Agents
Condition
Empagliflozin
Intervention (Drug)
Empagliflozin 10 MG
Intervention (Drug)
Insulin+Metformin+DPP4 inhibitor (DPP4I)
Lead sponsor
SINA Health Education and Welfare Trust (class: other)
Collaborator
Horizon Pharmaceutical Pvt Ltd (class: not stated)

Record details

Record id
cardio:ct-nct06145360
Content hash
0b73ee0a6d7bc840693eef31eddb6b74fb111a06e06c1b62f381fe00c41176b5